Remission in Global Airway Diseases: EUFOREA Consensus Paper - PubMed

3 hours ago

The therapeutic goal in chronic airway diseases is shifting from symptom control to disease remission, with biologics and allergen immunotherapy making remission achievable in severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and allergic rhinitis (AR).
An international expert panel achieved consensus on key principles: remission should be a therapeutic target regardless of initial disease severity; CRSwNP with nonallergic eosinophilic asthma and AR with allergic asthma should be viewed as a single disease; remission assessment requires separate subspecialty evaluation with combined approaches; pragmatic definitions with clinical utility are recommended; a 4-week recall window for symptom control and a 12-month period to define remission are preferred.
Remission represents an ambitious yet achievable goal, with practical guidance aimed at optimizing patient outcomes in global airway diseases.

Hasty Briefsbeta